Clinical trials
Kidney Transplant clinical trials
Below are recruiting kidney transplant clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07006831Recruiting
Blood study for kidney transplant patients
This study collects blood and leftover donor samples from kidney transplant recipients who need a biopsy. The goal is to improve monitoring after transplant.
San Diego, CaliforniaAges 18 years+ - NCT06206486Recruiting
Gut germs and pain after kidney transplant
This study looks at whether the germs in your gut (microbiome) and certain chemicals in your blood affect pain after a kidney transplant. By joining, you may help doctors better understand and manage pain for future kidney transplant patients.
Chicago, IllinoisAges 18 years+ - NCT06910527Recruiting
Testing blood and urine for kidney rejection signs
This study is for people with a kidney transplant who are in the hospital for a biopsy because their doctor suspects rejection. Researchers want to see if a simple blood or urine test can detect rejection, which might make future biopsies less necessary.
RouenAges 18 years+ - NCT06025240Recruiting
Better antibody monitoring after kidney transplant
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
Liverpool, MerseysideAges 18 years+ - NCT05175885Recruiting
Kidney transplant test using machine perfusion outside the body
This study tests a special way to keep and treat a donated kidney using a machine before it’s transplanted. The goal is to improve transplant outcomes for certain people on the kidney transplant waiting list.
ZaragozaAges 18 years+ - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT04954690Recruiting
Exercise program after kidney transplant for older adults
This trial tests a structured, coached exercise program for people who recently received a living-donor kidney and are coming from dialysis. It may help improve strength and daily function after transplant, especially if starting fitness is difficult.
San Francisco, CaliforniaAges 50 years+ - NCT04702022Recruiting
Extra PET scan to check for silent kidney transplant rejection
This study tests whether an additional PET scan can help detect and guide treatment for “subclinical” (silent) rejection in people with kidney transplants. It may help doctors spot problems earlier and manage them more appropriately.
Liège, LiègeAges 18 years+ - NCT05613010Recruiting
Tech tools to help young transplant patients take meds correctly
This study tests technology (like text reminders and an electronic pill box) to help adolescents and young adults who received a kidney or liver transplant take their medicines every day. It may help protect the transplant by improving medication adherence.
Baltimore, MarylandAges 13–25 - NCT02900040Recruiting
Kidney transplant database and blood sample access study
This trial is about setting up and using a kidney-transplant database linked to stored blood/tissue samples. It may help researchers better understand kidney transplant outcomes and improve future care.
LyonAges 18 years+ - NCT07143773RecruitingPhase 4
SGLT2i safety in kidney transplant patients without diabetes
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
OdenseAges 18 years+ - NCT05365672RecruitingPhase 2
Donor immune cell therapy during live kidney transplant
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
BerlinAges 18–69 - NCT06474273RecruitingPhase 3
Treating T-cell rejection after kidney transplant
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Lambton, New South WalesAges 2 years+ - NCT06288152Recruiting
Testing a protective solution for donated kidneys
This study tests a special solution given to the donor kidney during storage and transport, which may help protect the kidney before transplant. It is for adults with kidney failure receiving a deceased donor kidney.
London, OntarioAges 18 years+ - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+ - NCT07033858Recruiting
Short-term effects of Advograf plus Rapamiune after kidney transplant
This trial tests a combination of two medications (Advograf and Rapamiune) given shortly after kidney transplant to see how well they work and how safe they are. It may help improve long-term transplant health.
TehranAges 18 years+ - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Boston, MassachusettsAges 18–70 - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Birmingham, AlabamaAges 18–70 - NCT06130046Recruiting
Study of MR-proADM as a biomarker for kidney and liver transplant
This trial is testing a simple blood biomarker called MR-proADM to see if it can help doctors detect early signs of transplant rejection or poor kidney function after a kidney or liver transplant.
RomeAges 18–70 - NCT06972069RecruitingEarly Phase 1
Building tolerance to a new kidney with Sip-Tego
This study tests a new combination of medicines (Sip-Tego) to help your body accept a living donor kidney without needing lifelong anti-rejection drugs. It is for people with advanced kidney failure who are getting a first or second transplant.
Boston, MassachusettsAges 18–65 - NCT04128189RecruitingPhase 3
Shingrix vaccine for people waiting for a kidney transplant
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
Aurora, ColoradoAges 18–70 - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+ - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Kidney Transplant trials by city
Studies with a site in or near these metro areas.
Kidney Transplant trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for kidney transplant?
- Yes. Clin2 currently lists 244 recruiting kidney transplant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.